News
Market and company headlines
DOCAll
Loading
UBS maintains Healthpeak Properties (NYSE:DOC) with a Neutral and lowers the price target from $21.5 to $20.
Barclays analyst Richard Hightower maintains Healthpeak Properties (NYSE:DOC) with a Equal-Weight and lowers the price target from $24 to $21.
Healthpeak Properties (DOC) affirmed its monthly common dividend, setting a US$0.10167 per share payout for each month of the fourth quarter of 2026, equal to US$1.22 on an annualized basis. Healthpeak Properties shares trade at US$18.95, with a 1-year total shareholder return of 12.7% that contrasts with a 5-year total shareholder return that has declined 27.2%. The 30-day share price return is down 6.7% and the year-to-date share price return is up 17.0%, which hints that recent weakness...
Earlier this month, Healthpeak Properties’ board declared a monthly common stock cash dividend of $0.10167 per share for the fourth quarter of 2026, reflecting an annualized $1.22 per share, with record dates on October 19, November 13, and December 18, and payments scheduled for October 30, November 25, and December 30. This dividend affirmation comes after Healthpeak’s solid second quarter of 2026 and raised full-year FFO guidance, underscoring its ongoing effort to rebuild and grow the...
DENVER, October 01, 2026--Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, is scheduled to report third quarter 2026 financial results after the close of trading on the New York Stock Exchange on Monday, November 2, 2026.
DENVER, October 01, 2026--Healthpeak Properties, Inc. (NYSE: DOC) ("Healthpeak"), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, announced that on October 1, 2026, its Board of Directors declared a monthly common stock cash dividend of $0.10167 per share for the fourth quarter of 2026, payable on the payment dates set forth in the table below to stockholders of record as of the close of business on the corresponding record date in the table below.
In the past few days, Healthpeak Properties, Inc. raised its 2026 adjusted funds from operations guidance and lifted its same-store cash adjusted NOI growth outlook following stronger-than-expected Q2 results. This upgraded guidance highlights management’s increased confidence in the REIT’s operating performance and offers investors a clearer view of potential cash-flow resilience. Now, we’ll examine how Healthpeak’s upgraded 2026 adjusted FFO guidance could influence its existing...
Healthpeak Properties (DOC) raised its 2026 adjusted funds from operations guidance after solid Q2 operating results, and also lifted expectations for same-store cash adjusted NOI growth, giving investors fresh information on potential future cash flow. Healthpeak Properties shares trade at US$20.48, and after a year-to-date share price return of 26.42% and a 1-year total shareholder return of 17.32%, recent weakness over the past month suggests some of that momentum has cooled even as...
Healthpeak is an investment-grade, income and growth idea with a large-scale portfolio of outpatient, lab, and senior properties. See why DOC stock is a Buy.
Jefferies analyst Joe Dickstein assumes Healthpeak Properties (NYSE:DOC) with a Hold rating and lowers Price Target of $21.
This article first appeared on GuruFocus. Healthpeak Properties Inc (NYSE:DOC) recently announced a total dividend of $0.1 per share, with the ex-dividend date set for 2026-09-14. This includes a $0.1 per share cash dividend payable on 2026-09-25.
In uncertain markets, investors turn to dividend-yielding stocks. Benzinga provides latest analyst ratings & news for high-yielding stocks.
Occupancy gains in lab and outpatient medical segments drive raised full-year guidance.
Citigroup analyst Nick Joseph maintains Healthpeak Properties (NYSE:DOC) with a Neutral and raises the price target from $20 to $22.
Investors need to pay close attention to DOC stock based on the movements in the options market lately.
RBC Capital analyst Michael Carroll maintains Healthpeak Properties (NYSE:DOC) with a Outperform and raises the price target from $21 to $24.
Healthpeak Properties (DOC) shares are in focus after the company reported second quarter and first half 2026 results, alongside an increase in full year earnings guidance that signals greater management confidence. See our latest analysis for Healthpeak Properties. Against this earnings backdrop, Healthpeak Properties' recent share price performance has been mixed in the short term but stronger over longer periods, with a 1-day share price return of 1.47% and a year to date share price...
Healthpeak Properties has delivered a 35.1% return over the past year, yet the valuation checks send mixed messages, with the Discounted Cash Flow (DCF) intrinsic value estimate suggesting meaningful upside while earnings-based multiples point to a richer price tag. Over the last 12 months, Healthpeak Properties is up 35.1%, which puts more focus on whether the current share price still leaves a margin of safety. Future cash flow growth from its property portfolio can support the DCF-based...
